Anli Yang

12PUBLICATIONS
12CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersNanoscale characterisationApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 21, 2026
circPARPBP promotes cancer stemness and chemoresistance in triple-negative breast cancer through recruiting SRCAP complex to activate CCL20 transcription.

|Sep 12, 2025
Efficacy and Safety of T-DXd in HER2+ and Low/Zero Metastatic BCBM: A Retrospective Multicenter Real-World Study.

Qingru Zhou, Yuanyuan Li, Ni He

|May 17, 2024
MLLT6/ATF2 Axis Restrains Breast Cancer Progression by Driving DDIT3/4 Expression.

Qing Yu, Jiayi Zhao, Anli Yang

|Jan 21, 2022
A risk scoring system based on tumor microenvironment cells to predict prognosis and immune activity in triple-negative breast cancer.

Anli Yang, Minqing Wu, Mengqian Ni

|Jan 05, 2022
Photocontrolled chondrogenic differentiation and long-term tracking of mesenchymal stem cells in vivo by upconversion nanoparticles.

Zihan Yang, Xichao Wang, Guohai Liang

|Jul 17, 2021
Melatonin inhibits triple-negative breast cancer progression through the Lnc049808-FUNDC1 pathway.

Anli Yang, Fu Peng, Lewei Zhu

Pageof 2

Frequent Collaborators

2 joint publications

Jinming Li

1 joint publications

Weikai Xiao

1 joint publications

Kaipeng Wang

1 joint publications

Qing Yu